2023

A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases.
Brum WS, Cullen NC, Janelidze S, Ashton NJ, Zimmer ER, Therriault J, Benedet AL, Rahmouni N, Tissot C, Stevenson J, Servaes S, Triana-Baltzer G, Kolb HC, Palmqvist S, Stomrud E, Rosa-Neto P, Blennow K, Hansson O. Nat Aging. 2023 Aug 31. doi: 10.1038/s43587-023-00471-5.

Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.
Zhao JH, Stacey D, Eriksson N, Macdonald-Dunlop E, Hedman ÅK, Kalnapenkis A, Enroth S, Cozzetto D, Digby-Bell J, Marten J, Folkersen L, Herder C, Jonsson L, Bergen SE, Gieger C, Needham EJ, Surendran P; Estonian Biobank Research Team; Paul DS, Polasek O, Thorand B, Grallert H, Roden M, Võsa U, Esko T, Hayward C, Johansson Å, Gyllensten U, Powell N, Hansson O, Mattsson-Carlgren N, Joshi PK, Danesh J, Padyukov L, Klareskog L, Landén M, Wilson JF, Siegbahn A, Wallentin L, Mälarstig A, Butterworth AS, Peters JE. Nat Immunol. 2023 Sep;24(9):1540-1551. doi: 10.1038/s41590-023-01588-w.

Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders.
Eratne D, Kang M, Malpas C, Simpson-Yap S, Lewis C, Dang C, Grewal J, Coe A, Dobson H, Keem M, Chiu WH, Kalincik T, Ooi S, Darby D, Brodtmann A, Hansson O, Janelidze S, Blennow K, Zetterberg H, Walker A, Dean O, Berk M, Wannan C, Pantelis C, Loi SM, Walterfang M, Berkovic SF, Santillo AF, Velakoulis D. Aust N Z J Psychiatry. 2023 Jul 21:48674231187312. doi: 10.1177/00048674231187312.

Cognitive effects of Lewy body pathology in clinically unimpaired individuals.
Palmqvist S, Rossi M, Hall S, Quadalti C, Mattsson-Carlgren N, Dellavalle S, Tideman P, Pereira JB, Nilsson MH, Mammana A, Janelidze S, Baiardi S, Stomrud E, Parchi P, Hansson O. Nat Med. 2023 Aug;29(8):1971-1978. doi: 10.1038/s41591-023-02450-0.

Clinical effects of Lewy body pathology in cognitively impaired individuals.
Quadalti C, Palmqvist S, Hall S, Rossi M, Mammana A, Janelidze S, Dellavalle S, Mattsson-Carlgren N, Baiardi S, Stomrud E, Hansson O, Parchi P. Nat Med. 2023 Aug;29(8):1964-1970. doi: 10.1038/s41591-023-02449-7.

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease.
Horie K, Salvadó G, Barthélemy NR, Janelidze S, Li Y, He Y, Saef B, Chen CD, Jiang H, Strandberg O, Pichet Binette A, Palmqvist S, Sato C, Sachdev P, Koyama A, Gordon BA, Benzinger TLS, Holtzman DM, Morris JC, Mattsson-Carlgren N, Stomrud E, Ossenkoppele R, Schindler SE, Hansson O, Bateman RJ. Nat Med. 2023 Aug;29(8):1954-1963. doi: 10.1038/s41591-023-02443-z.

Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms.
Smith R, Hägerström D, Pawlik D, Klein G, Jögi J, Ohlsson T, Stomrud E, Hansson O. JAMA Neurol. 2023 Jul 1;80(7):749-756. doi: 10.1001/jamaneurol.2023.1323.

Blood biomarkers for Alzheimer’s disease in clinical practice and trials.
Hansson O, Blennow K, Zetterberg H, Dage J. Nat Aging. 2023 May;3(5):506-519. doi: 10.1038/s43587-023-00403-3

Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer’s disease.
Oeckl P, Janelidze S, Halbgebauer S, Stomrud E, Palmqvist S, Otto M, Hansson O. Alzheimers Dement. 2023 Apr 27. doi: 10.1002/alz.13103

Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A, Binette AP, Vogel JW, Klein G, Borroni E, Tonietto M, Strandberg O, Mattsson-Carlgren N, Palmqvist S, Pontecorvo MJ, Iaccarino L, Stomrud E, Ossenkoppele R, Smith R, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. JAMA Neurol. 2023 Jun 1;80(6):614-623. doi: 10.1001/jamaneurol.2023.1067.

Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.
Cicognola C, Mattsson-Carlgren N, van Westen D, Zetterberg H, Blennow K, Palmqvist S, Ahmadi K, Strandberg O, Stomrud E, Janelidze S, Hansson O. Neurology. 2023 Jul 4;101(1):e30-e39. doi: 10.1212/WNL.0000000000207358.

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology.
Pereira JB, Janelidze S, Strandberg O, Whelan CD, Zetterberg H, Blennow K, Palmqvist S, Stomrud E, Mattsson-Carlgren N, Hansson O. Nat Aging. 2022 Dec;2(12):1138-1144. doi: 10.1038/s43587-022-00310-z.

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease.
Barthélemy NR, Saef B, Li Y, Gordon BA, He Y, Horie K, Stomrud E, Salvadó G, Janelidze S, Sato C, Ovod V, Henson RL, Fagan AM, Benzinger TLS, Xiong C, Morris JC, Hansson O, Bateman RJ, Schindler SE. Nat Aging. 2023 Apr;3(4):391-401. doi: 10.1038/s43587-023-00380-7.

Age-related and amyloid-beta-independent tau deposition and its downstream effects.
Wuestefeld A, Pichet Binette A, Berron D, Spotorno N, van Westen D, Stomrud E, Mattsson-Carlgren N, Strandberg O, Smith R, Palmqvist S, Glenn T, Moes S, Honer M, Arfanakis K, Barnes LL, Bennett DA, Schneider JA, Wisse LEM, Hansson O. Brain. 2023 Aug 1;146(8):3192-3205. doi: 10.1093/brain/awad135.

Anterior cingulate sulcation is associated with onset and survival in frontotemporal dementia.
Harper L, de Boer S, Lindberg O, Lätt J, Cullen N, Clark L, Irwin D, Massimo L, Grossman M, Hansson O, Pijnenburg Y, McMillan CT, Santillo AF. medRxiv. 2023 Mar 31:2023.03.30.23287945. doi: 10.1101/2023.03.30.23287945.

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios.
Janelidze S, Barthélemy NR, He Y, Bateman RJ, Hansson O. JAMA Neurol. 2023 May 1;80(5):516-522. doi: 10.1001/jamaneurol.2023.0199.

Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis.
Bocancea DI, Svenningsson AL, van Loenhoud AC, Groot C, Barkhof F, Strandberg O, Smith R; Alzheimer’s Disease Neuroimaging Initiative; La Joie R, Rosen HJ, Pontecorvo MJ, Rabinovici GD, van der Flier WM, Hansson O, Ossenkoppele R. Brain. 2023 Sep 1;146(9):3719-3734. doi: 10.1093/brain/awad100.

Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App^NL-F/NL-F knock-in mouse model of Alzheimer’s disease.
Andersson E, Schultz N, Saito T, Saido TC, Blennow K, Gouras GK, Zetterberg H, Hansson O. Alzheimers Res Ther. 2023 Mar 25;15(1):64. doi: 10.1186/s13195-023-01196-8.

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease.
Cullen NC, Janelidze S, Stomrud E, Bateman RJ, Palmqvist S, Hansson O, Mattsson-Carlgren N. Brain Commun. 2023 Jan 24;5(2):fcad015. doi: 10.1093/braincomms/fcad015. eCollection 2023.

Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.
Gertje EC, Janelidze S, van Westen D, Cullen N, Stomrud E, Palmqvist S, Hansson O, Mattsson-Carlgren N. Neurology. 2023 Apr 25;100(17):e1812-e1824. doi: 10.1212/WNL.0000000000207113.

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
Mattsson-Carlgren N, Salvadó G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, Ossenkoppele R, Betthauser TJ, Cody KA, Jonaitis EM, Langhough R, Palmqvist S, Blennow K, Janelidze S, Johnson SC, Hansson O. JAMA Neurol. 2023 Apr 1;80(4):360-369. doi: 10.1001/jamaneurol.2022.5272.

Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer’s disease.
Pascoal TA, Leuzy A, Therriault J, Chamoun M, Lussier F, Tissot C, Strandberg O, Palmqvist S, Stomrud E, Ferreira PCL, Ferrari-Souza JP, Smith R, Benedet AL, Gauthier S, Hansson O, Rosa-Neto P. Alzheimers Dement (Amst). 2023 Jan 30;15(1):e12390. doi: 10.1002/dad2.12390.

Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.
Leuzy A, Mattsson-Carlgren N, Cullen NC, Stomrud E, Palmqvist S, La Joie R, Iaccarino L, Zetterberg H, Rabinovici G, Blennow K, Janelidze S, Hansson O. Alzheimers Dement. 2023 Jul;19(7):2994-3004. doi: 10.1002/alz.12897.

Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study.
Salvadó G, Larsson V, Cody KA, Cullen NC, Jonaitis EM, Stomrud E, Kollmorgen G, Wild N, Palmqvist S, Janelidze S, Mattsson-Carlgren N, Zetterberg H, Blennow K, Johnson SC, Ossenkoppele R, Hansson O. Alzheimers Dement. 2023 Jul;19(7):2943-2955. doi: 10.1002/alz.12907.

Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.
Smith R, Cullen NC, Pichet Binette A, Leuzy A, Blennow K, Zetterberg H, Klein G, Borroni E, Ossenkoppele R, Janelidze S, Palmqvist S, Mattsson-Carlgren N, Stomrud E, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement. 2023 Jun;19(6):2497-2507. doi: 10.1002/alz.12875.

Novel insights regarding the measurement properties of the SCOPA-AUT.
Westergren A, Wictorin K, Hansson O, Hagell P. BMC Neurol. 2022 Dec 13;22(1):478. doi: 10.1186/s12883-022-03008-2.

[¹⁸F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes.
Santillo AF, Leuzy A, Honer M, Landqvist Waldö M, Tideman P, Harper L, Ohlsson T, Moes S, Giannini L, Jögi J, Groot C, Ossenkoppele R, Strandberg O, van Swieten J, Smith R, Hansson O. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1371-1383. doi: 10.1007/s00259-022-06065-4.

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum.
Gobom J, Benedet AL, Mattsson-Carlgren N, Montoliu-Gaya L, Schultz N, Ashton NJ, Janelidze S, Servaes S, Sauer M, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brinkmalm G, Zetterberg H, Hansson O, Rosa-Neto P, Blennow K. Mol Neurodegener. 2022 Dec 12;17(1):81. doi: 10.1186/s13024-022-00586-0.

The genetic regulation of protein expression in cerebrospinal fluid.
Hansson O, Kumar A, Janelidze S, Stomrud E, Insel PS, Blennow K, Zetterberg H, Fauman E, Hedman ÅK, Nagle MW, Whelan CD, Baird D, Mälarstig A, Mattsson-Carlgren N. EMBO Mol Med. 2023 Jan 11;15(1):e16359. doi: 10.15252/emmm.202216359.

Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction are Altered in Parkinson’s Disease and Related Disorders.
Nilsson J, Constantinescu J, Nellgård B, Jakobsson P, Brum WS, Gobom J, Forsgren L, Dalla K, Constantinescu R, Zetterberg H, Hansson O, Blennow K, Bäckström D, Brinkmalm A. Mov Disord. 2023 Feb;38(2):267-277. doi: 10.1002/mds.29287.

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring.
Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, Karikari TK, González-Ortiz F, Di Molfetta G, Meda FJ, Jonaitis EM, Koscik RL, Cody K, Betthauser TJ, Li Y, Vanmechelen E, Palmqvist S, Stomrud E, Bateman RJ, Zetterberg H, Johnson SC, Blennow K, Hansson O. Nat Med. 2022 Dec;28(12):2555-2562. doi: 10.1038/s41591-022-02074-w.

Performance of [¹⁸F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy.
Oliveira Hauer K, Pawlik D, Leuzy A, Janelidze S, Hall S, Hansson O, Smith R. Parkinsonism Relat Disord. 2023 Jan;106:105226. doi: 10.1016/j.parkreldis.2022.11.018.

Gray matter hypoperfusion is a late pathological event in the course of Alzheimer’s disease.
Ahmadi K, Pereira JB, Berron D, Vogel J, Ingala S, Strandberg OT, Janelidze S, Barkhof F, Pfeuffer J, Knutsson L, van Westen D, Palmqvist S, Mutsaerts HJ, Hansson O. J Cereb Blood Flow Metab. 2023 Apr;43(4):565-580. doi: 10.1177/0271678X221141139.

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, Stomrud E, Tideman P, Ohlsson T, Jögi J, Johnson K, Sperling R, Dore V, Masters CL, Rowe C, Visser D, van Berckel BNM, van der Flier WM, Baker S, Jagust WJ, Wiste HJ, Petersen RC, Jack CR Jr, Hansson O. Nat Med. 2022 Nov;28(11):2381-2387. doi: 10.1038/s41591-022-02049-x.

CSF ferritin in the clinicopathological progression of Alzheimer’s disease and associations with APOE and inflammation biomarkers.
Ayton S, Janelidze S, Kalinowski P, Palmqvist S, Belaidi AA, Stomrud E, Roberts A, Roberts B, Hansson O, Bush AI. J Neurol Neurosurg Psychiatry. 2023 Mar;94(3):211-219. doi: 10.1136/jnnp-2022-330052.

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease.
Pichet Binette A, Franzmeier N, Spotorno N, Ewers M, Brendel M, Biel D; Alzheimer’s Disease Neuroimaging Initiative; Strandberg O, Janelidze S, Palmqvist S, Mattsson-Carlgren N, Smith R, Stomrud E, Ossenkoppele R, Hansson O. Nat Commun. 2022 Nov 4;13(1):6635. doi: 10.1038/s41467-022-34129-4.

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease.
Blennow K, Stomrud E, Zetterberg H, Borlinghaus N, Corradini V, Manuilova E, Müller-Hübner L, Quevenco FC, Rutz S, Hansson O. Clin Chem Lab Med. 2022 Oct 24;61(2):234-244. doi: 10.1515/cclm-2022-0516.

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy.
Svenningsson AL, Stomrud E, Palmqvist S, Hansson O, Ossenkoppele R. Alzheimers Res Ther. 2022 Oct 4;14(1):144. doi: 10.1186/s13195-022-01081-w.

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease.
Rubinski A, Franzmeier N, Dewenter A, Luan Y, Smith R, Strandberg O, Ossenkoppele R, Dichgans M, Hansson O, Ewers M; Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimers Res Ther. 2022 Sep 24;14(1):139. doi: 10.1186/s13195-022-01074-9.

Confounding factors of Alzheimer’s disease plasma biomarkers and their impact on clinical performance.
Pichet Binette A, Janelidze S, Cullen N, Dage JL, Bateman RJ, Zetterberg H, Blennow K, Stomrud E, Mattsson-Carlgren N, Hansson O. Alzheimers Dement. 2023 Apr;19(4):1403-1414. doi: 10.1002/alz.12787.

Clinical performance and robustness evaluation of plasma amyloid-β_42/40prescreening.
Rabe C, Bittner T, Jethwa A, Suridjan I, Manuilova E, Friesenhahn M, Stomrud E, Zetterberg H, Blennow K, Hansson O; Alzheimer’s Disease Neuroimaging Initiative† and the Swedish BioFINDER study. Alzheimers Dement. 2023 Apr;19(4):1393-1402. doi: 10.1002/alz.12801.

Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease.
Spotorno N, Strandberg O, Vis G, Stomrud E, Nilsson M, Hansson O. Brain. 2023 Apr 19;146(4):1602-1614. doi: 10.1093/brain/awac343.

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease.
Janelidze S, Bali D, Ashton NJ, Barthélemy NR, Vanbrabant J, Stoops E, Vanmechelen E, He Y, Dolado AO, Triana-Baltzer G, Pontecorvo MJ, Zetterberg H, Kolb H, Vandijck M, Blennow K, Bateman RJ, Hansson O. Brain. 2023 Apr 19;146(4):1592-1601. doi: 10.1093/brain/awac333.

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
Groot C, Smith R, Stomrud E, Binette AP, Leuzy A, Wuestefeld A, Wisse LEM, Palmqvist S, Mattsson-Carlgren N, Janelidze S, Strandberg O, Ossenkoppele R, Hansson O. Brain. 2023 Apr 19;146(4):1580-1591. doi: 10.1093/brain/awac329.

2022

Spatial Navigation and Its Association With Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia.
Tangen GG, Nilsson MH, Stomrud E, Palmqvist S, Hansson O. Neurology. 2022 Nov 8;99(19):e2081-e2091. doi: 10.1212/WNL.0000000000201106.

Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading.
Frontzkowski L, Ewers M, Brendel M, Biel D, Ossenkoppele R, Hager P, Steward A, Dewenter A, Römer S, Rubinski A, Buerger K, Janowitz D, Binette AP, Smith R, Strandberg O, Carlgren NM, Dichgans M, Hansson O, Franzmeier N. Nat Commun. 2022 Aug 20;13(1):4899. doi: 10.1038/s41467-022-32592-7.

An accurate fully automated panel of plasma biomarkers for Alzheimer’s disease.
Palmqvist S, Stomrud E, Cullen N, Janelidze S, Manuilova E, Jethwa A, Bittner T, Eichenlaub U, Suridjan I, Kollmorgen G, Riepe M, von Arnim CAF, Tumani H, Hager K, Heidenreich F, Mattsson-Carlgren N, Zetterberg H, Blennow K, Hansson O. Alzheimers Dement. 2023 Apr;19(4):1204-1215. doi: 10.1002/alz.12751.

Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.
Borland E, Edgar C, Stomrud E, Cullen N, Hansson O, Palmqvist S. Neurology. 2022 Sep 13;99(11):e1142-e1153. doi: 10.1212/WNL.0000000000200817.

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease.
Hall S, Orrù CD, Serrano GE, Galasko D, Hughson AG, Groveman BR, Adler CH, Beach TG, Caughey B, Hansson O. Acta Neuropathol Commun. 2022 Jun 22;10(1):90. doi: 10.1186/s40478-022-01388-7.

Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE ϵ4 carriers.
Spotorno N, Najac C, Stomrud E, Mattsson-Carlgren N, Palmqvist S, van Westen D, Ronen I, Hansson O. Brain Commun. 2022 May 22;4(3):fcac135. doi: 10.1093/braincomms/fcac135.

Test-retest variability of plasma biomarkers in Alzheimer’s disease and its effects on clinical prediction models.
Cullen NC, Janelidze S, Mattsson-Carlgren N, Palmqvist S, Bittner T, Suridjan I, Jethwa A, Kollmorgen G, Brum WS, Zetterberg H, Blennow K, Stomrud E, Hansson O. Alzheimers Dement. 2022 Jun 14:10.1002/alz.12706. doi: 10.1002/alz.12706.

β-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease.
Kumar A, Janelidze S, Stomrud E, Palmqvist S, Hansson O, Mattsson-Carlgren N; for the Alzheimer’s Disease Neuroimaging Initiative. Neurology. 2022 May 31;99(5):e476-87. doi: 10.1212/WNL.0000000000200605.

Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217.
Groot C, Cicognola C, Bali D, Triana-Baltzer G, Dage JL, Pontecorvo MJ, Kolb HC, Ossenkoppele R, Janelidze S, Hansson O. Alzheimers Res Ther. 2022 May 14;14(1):67. doi: 10.1186/s13195-022-01005-8.

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients.
Pichet Binette A, Palmqvist S, Bali D, Farrar G, Buckley CJ, Wolk DA, Zetterberg H, Blennow K, Janelidze S, Hansson O. Alzheimers Res Ther. 2022 Mar 29;14(1):46. doi: 10.1186/s13195-022-00990-0.

Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer’s Disease Pathology and Cognitive Decline.
Johansson M, Stomrud E, Johansson PM, Svenningsson A, Palmqvist S, Janelidze S, van Westen D, Mattsson-Carlgren N, Hansson O. Biol Psychiatry. 2022 Jan 31:S0006-3223(22)00053-1. doi: 10.1016/j.biopsych.2022.01.012.

Midsagittal corpus callosal thickness and cognitive impairment in Parkinson’s disease.
Owens-Walton C, Adamson C, Walterfang M, Hall S, van Westen D, Hansson O, Shaw M, Looi JCL. Eur J Neurosci. 2022 Apr;55(7):1859-1872. doi: 10.1111/ejn.15640. 

Subtypes of Alzheimer’s disease: questions, controversy, and meaning.
Vogel JW, Hansson O. Trends Neurosci. 2022 May;45(5):342-345. doi: 10.1016/j.tins.2022.02.001. 

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
Mattsson-Carlgren N, Grinberg LT, Boxer A, Ossenkoppele R, Jonsson M, Seeley W, Ehrenberg A, Spina S, Janelidze S, Rojas-Martinex J, Rosen H, La Joie R, Lesman-Segev O, Iaccarino L, Kollmorgen G, Ljubenkov P, Eichenlaub U, Gorno-Tempini ML, Miller B, Hansson O, Rabinovici GD. Neurology. 2022 Mar 15;98(11):e1137-e1150. doi: 10.1212/WNL.0000000000200040.

The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.
Ayton S, Hall S, Janelidze S, Kalinowski P, Palmqvist S, Belaidi AA, Roberts B, Roberts A, Stomrud E, Bush AI, Hansson O. Mov Disord. 2022 Feb 8. doi: 10.1002/mds.28958.

Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer’s disease and frontotemporal disorders in clinical settings.
Eratne D, Loi SM, Li QX, Stehmann C, Malpas CB, Santillo A, Janelidze S, Cadwallader C, Walia N, Ney B, Lewis V, Senesi M, Fowler C, McGlade A, Varghese S, Ravanfar P, Kelso W, Farrand S, Keem M, Kang M, Goh AMY, Dhiman K, Gupta V, Watson R, Yassi N, Kaylor-Hughes C, Kanaan R, Perucca P, Dobson H, Vivash L, Ali R, O’Brien TJ, Hansson O, Zetterberg H, Blennow K, Walterfang M, Masters CL, Berkovic SF, Collins S, Velakoulis D; MiND Study Group. Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12549. 

Components of gait in people with and without mild cognitive impairment.
Lindh-Rengifo M, Jonasson SB, Ullén S, Stomrud E, Palmqvist S, Mattsson-Carlgren N, Hansson O, Nilsson MH. Gait Posture. 2022 Mar;93:83-89. doi: 10.1016/j.gaitpost.2022.01.012.

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ; Amyloid Biomarker Study Group, Aarsland D, Alcolea D, Altomare D, von Arnim C, Baiardi S, Baldeiras I, Barthel H, Bateman RJ, Van Berckel B, Binette AP, Blennow K, Boada M, Boecker H, Bottlaender M, den Braber A, Brooks DJ, Van Buchem MA, Camus V, Carill JM, Cerman J, Chen K, Chételat G, Chipi E, Cohen AD, Daniels A, Delarue M, Didic M, Drzezga A, Dubois B, Eckerström M, Ekblad LL, Engelborghs S, Epelbaum S, Fagan AM, Fan Y, Fladby T, Fleisher AS, Van der Flier WM, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Frings L, Frisoni GB, Fröhlich L, Gabryelewicz T, Gertz HJ, Gill KD, Gkatzima O, Gómez-Tortosa E, Grimmer T, Guedj E, Habeck CG, Hampel H, Handels R, Hansson O, Hausner L, Hellwig S, Heneka MT, Herukka SK, Hildebrandt H, Hodges J, Hort J, Huang CC, Iriondo AJ, Itoh Y, Ivanoiu A, Jagust WJ, Jessen F, Johannsen P, Johnson KA, Kandimalla R, Kapaki EN, Kern S, Kilander L, Klimkowicz-Mrowiec A, Klunk WE, Koglin N, Kornhuber J, Kramberger MG, Kuo HC, Van Laere K, Landau SM, Landeau B, Lee DY, de Leon M, Leyton CE, Lin KJ, Lleó A, Löwenmark M, Madsen K, Maier W, Marcusson J, Marquié M, Martinez-Lage P, Maserejian N, Mattsson N, de Mendonça A, Meyer PT, Miller BL, Minatani S, Mintun MA, Mok VCT, Molinuevo JL, Morbelli SD, Morris JC, Mroczko B, Na DL, Newberg A, Nobili F, Nordberg A, Olde Rikkert MGM, de Oliveira CR, Olivieri P, Orellana A, Paraskevas G, Parchi P, Pardini M, Parnetti L, Peters O, Poirier J, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Reiman EM, Rinne JO, Rodrigue KM, Rodríguez-Rodriguez E, Roe CM, Rosa-Neto P, Rosen HJ, Rot U, Rowe CC, Rüther E, Ruiz A, Sabri O, Sakhardande J, Sánchez-Juan P, Sando SB, Santana I, Sarazin M, Scheltens P, Schröder J, Selnes P, Seo SW, Silva D, Skoog I, Snyder PJ, Soininen H, Sollberger M, Sperling RA, Spiru L, Stern Y, Stomrud E, Takeda A, Teichmann M, Teunissen CE, Thompson LI, Tomassen J, Tsolaki M, Vandenberghe R, Verbeek MM, Verhey FRJ, Villemagne V, Villeneuve S, Vogelgsang J, Waldemar G, Wallin A, Wallin ÅK, Wiltfang J, Wolk DA, Yen TC, Zboch M, Zetterberg H. JAMA Neurol. 2022 Mar 1;79(3):228-243. doi: 10.1001/jamaneurol.2021.5216.

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, Borroni E, Janelidze S, Ohlsson T, Jögi J, Ossenkoppele R, Palmqvist S, Mattsson-Carlgren N, Klein G, Stomrud E, Hansson O. JAMA Neurol. 2022 Feb 1;79(2):149-158. doi: 10.1001/jamaneurol.2021.4654.

Blood-based biomarkers for Alzheimer’s disease.
Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. EMBO Mol Med. 2022 Jan 11;14(1):e14408. doi: 10.15252/emmm.202114408.

Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation.
Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, van der Flier WM, Mielke MM, Del Campo M. Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6. 

Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes.
Ygland Rödström E, Mattsson-Carlgren N, Janelidze S, Hansson O, Puschmann A. J Parkinsons Dis. 2022;12(2):571-584. doi: 10.3233/JPD-212866.

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.
Pavlik VN, Burnham SC, Kass JS, Helmer C, Palmqvist S, Vassilaki M, Dartigues JF, Hansson O, Masters CL, Pérès K, Petersen RC, Stomrud E, Butler L, Coloma PM, Teitsma XM, Doody R, Sano M; CONCORD-AD investigators. J Alzheimers Dis. 2022;85(1):31-45. doi: 10.3233/JAD-210525.

Insights on Genetic and Environmental Factors in Parkinson’s Disease from a Regional Swedish Case-Control Cohort.
Brolin K, Bandres-Ciga S, Blauwendraat C, Widner H, Odin P, Hansson O, Puschmann A, Swanberg M. J Parkinsons Dis. 2022;12(1):153-171. doi: 10.3233/JPD-212818.

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.
Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, Ashton NJ, Pesini P, Sarasa L, Allué JA, Teunissen CE, Dage JL, Blennow K, Mattsson-Carlgren N, Hansson O. Alzheimers Dement. 2022 Feb;18(2):283-293. doi: 10.1002/alz.12395.

Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis.
Bjurström MF, Bodelsson M, Irwin MR, Orbjörn C, Hansson O, Mattsson-Carlgren N. Pain Pract. 2022 Jan;22(1):66-82. doi: 10.1111/papr.13051.

The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.
Franzmeier N, Ossenkoppele R, Brendel M, Rubinski A, Smith R, Kumar A, Mattsson-Carlgren N, Strandberg O, Duering M, Buerger K, Dichgans M, Hansson O, Ewers M; Alzheimer’s Disease Neuroimaging Initiative (ADNI)* and the Swedish BioFINDER study. Alzheimers Dement. 2022 Jan;18(1):103-115. doi: 10.1002/alz.12371.

Prenatal Gyrification Pattern Affects Age at Onset in Frontotemporal Dementia.
Harper L, Lindberg O, Bocchetta M, Todd EG, Strandberg O, van Westen D, Stomrud E, Landqvist Waldö M, Wahlund LO, Hansson O, Rohrer JD, Santillo A.Cereb Cortex. 2022 Jan 17:bhab457. doi: 10.1093/cercor/bhab457. 

Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.
Tideman P, Stomrud E, Leuzy A, Mattsson-Carlgren N, Palmqvist S, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.Neurology. 2022 Jan 12:10.1212/WNL.0000000000013299. doi: 10.1212/WNL.0000000000013299.

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels.
Wennström M, Janelidze S, Nilsson KPR; Netherlands Brain Bank, Serrano GE, Beach TG, Dage JL, Hansson O. Acta Neuropathol Commun. 2022 Jan 6;10(1):3. doi: 10.1186/s40478-021-01307-2.

2021

Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline.
Cullen N, Janelidze S, Palmqvist S, Stomrud E, Mattsson-Carlgren N, Hansson O. Neurology. 2021 Dec 22:10.1212/WNL.0000000000013228. doi: 10.1212/WNL.0000000000013228. PMID: 34937781

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, Borroni E, Janelidze S, Ohlsson T, Jögi J, Ossenkoppele R, Palmqvist S, Mattsson-Carlgren N, Klein G, Stomrud E, Hansson O.JAMA Neurol. 2021 Dec 20:e214654. doi: 10.1001/jamaneurol.2021.4654..PMID: 34928318 Free PMC article.

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, Leslie SM, Masters CL, Fowler CJ, Trojanowski JQ, Korecka M, Martins RN, Janelidze S, Hansson O, Bateman RJ. Neurology. 2021 Dec 14:10.1212/WNL.0000000000013211. doi: 10.1212/WNL.0000000000013211..PMID: 34906975

The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals.
Salvadó G, Ferreira D, Operto G, Cumplido-Mayoral I, Arenaza-Urquijo EM, Cacciaglia R, Falcon C, Vilor-Tejedor N, Minguillon C, Groot C, van der Flier WM, Barkhof F, Scheltens P, Ossenkoppele R, Kern S, Zettergren A, Skoog I, Hort J, Stomrud E, van Westen D, Hansson O, Molinuevo JL, Wahlund LO, Westman E, Gispert JD; ALFA study†, BioFINDER, ADNI.Alzheimers Dement. 2021 Dec 8. doi: 10.1002/alz.12487. 

Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group.
Verberk IMW, Misdorp EO, Koelewijn J, Ball AJ, Blennow K, Dage JL, Fandos N, Hansson O, Hirtz C, Janelidze S, Kang S, Kirmess K, Kindermans J, Lee R, Meyer MR, Shan D, Shaw LM, Waligorska T, West T, Zetterberg H, Edelmayer RM, Teunissen CE. Alzheimers Dement. 2021 Nov 29. doi: 10.1002/alz.12510. 

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.
Pavlik VN, Burnham SC, Kass JS, Helmer C, Palmqvist S, Vassilaki M, Dartigues JF, Hansson O, Masters CL, Pérès K, Petersen RC, Stomrud E, Butler L, Coloma PM, Teitsma XM, Doody R, Sano M; CONCORD-AD investigators.J Alzheimers Dis. 2022;85(1):31-45. doi: 10.3233/JAD-210525.

The global Alzheimer’s Association round robin study on plasma amyloid β methods.
Pannee J, Shaw LM, Korecka M, Waligorska T, Teunissen CE, Stoops E, Vanderstichele HMJ, Mauroo K, Verberk IMW, Keshavan A, Pesini P, Sarasa L, Pascual-Lucas M, Fandos N, Allué JA, Portelius E, Andreasson U, Yoda R, Nakamura A, Kaneko N, Yang SY, Liu HC, Palme S, Bittner T, Mawuenyega KG, Ovod V, Bollinger J, Bateman RJ, Li Y, Dage JL, Stomrud E, Hansson O, Schott JM, Blennow K, Zetterberg H. Alzheimers Dement (Amst). 2021 Oct 14;13(1):e12242. doi: 10.1002/dad2.12242. eCollection 2021.

Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease.
Kumar A, Shoai M, Palmqvist S, Stomrud E, Hardy J, Mattsson-Carlgren N, Hansson O. Sci Rep. 2021 Oct 6;11(1):19853. doi: 10.1038/s41598-021-99310-z.

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
Janelidze S, Teunissen CE, Zetterberg H, Allué JA, Sarasa L, Eichenlaub U, Bittner T, Ovod V, Verberk IMW, Toba K, Nakamura A, Bateman RJ, Blennow K, Hansson O. JAMA Neurol. 2021 Nov 1;78(11):1375-1382. doi: 10.1001/jamaneurol.2021.3180.

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
Leuzy A, Janelidze S, Mattsson-Carlgren N, Palmqvist S, Jacobs D, Cicognola C, Stomrud E, Vanmechelen E, Dage JL, Hansson O. Neurology. 2021 Oct 26;97(17):e1681-e1694. doi: 10.1212/WNL.0000000000012727. Epub 2021 Sep 7.

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, Spina S, Allen IE, Cobigo Y, Heuer H, VandeVrede L, Proctor NK, Lago AL, Baker S, Sivasankaran R, Kieloch A, Kinhikar A, Yu L, Valentin MA, Jeromin A, Zetterberg H, Hansson O, Mattsson-Carlgren N, Graham D, Blennow K, Kramer JH, Grinberg LT, Seeley WW, Rosen H, Boeve BF, Miller BL, Teunissen CE, Rabinovici GD, Rojas JC, Dage JL, Boxer AL;  Advancing Research and Treatment for Frontotemporal Lobar Degeneration investigators.Lancet Neurol. 2021 Sep;20(9):739-752. doi: 10.1016/S1474-4422(21)00214-3.

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum.
Pelkmans W, Ossenkoppele R, Dicks E, Strandberg O, Barkhof F, Tijms BM, Pereira JB, Hansson O. Alzheimers Res Ther. 2021 Aug 13;13(1):138. doi: 10.1186/s13195-021-00876-7.

Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience.
Håkansson C, Tamaddon A, Andersson H, Torisson G, Mårtensson G, Truong M, Annertz M, Londos E, Björkman-Burtscher IM, Hansson O, van Westen D. Eur Radiol. 2022 Feb;32(2):1127-1134. doi: 10.1007/s00330-021-08177-1. Epub 2021 Jul 30.

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease.
Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, Zetterberg H, Stomrud E, Ashton NJ, Blennow K, Hansson O. Brain. 2021 Dec 16;144(11):3505-3516. doi: 10.1093/brain/awab223.

Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers.
Ossenkoppele R, Reimand J, Smith R, Leuzy A, Strandberg O, Palmqvist S, Stomrud E, Zetterberg H; Alzheimer’s Disease Neuroimaging Initiative, Scheltens P, Dage JL, Bouwman F, Blennow K, Mattsson-Carlgren N, Janelidze S, Hansson O. EMBO Mol Med. 2021 Aug 9;13(8):e14398. doi: 10.15252/emmm.202114398. Epub 2021 Jul 13.

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, Palmqvist S, Olsson T, Jögi J, Stormrud E, Cho H, Ryu YH, Choi JY, Boxer AL, Gorno-Tempini ML, Miller BL, Soleimani-Meigooni D, Iaccarino L, La Joie R, Baker S, Borroni E, Klein G, Pontecorvo MJ, Devous MD Sr, Jagust WJ, Lyoo CH, Rabinovici GD, Hansson O. JAMA Neurol. 2021 Aug 1;78(8):961-971. doi: 10.1001/jamaneurol.2021.1858.

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.
Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, Ashton NJ, Pesini P, Sarasa L, Allué JA, Teunissen CE, Dage JL, Blennow K, Mattsson-Carlgren N, Hansson O. Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12395. 

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations.
Cullen NC, Leuzy A, Janelidze S, Palmqvist S, Svenningsson AL, Stomrud E, Dage JL, Mattsson-Carlgren N, Hansson O. Nat Commun. 2021 Jun 11;12(1):3555. doi: 10.1038/s41467-021-23746-0.

A multicentre validation study of the diagnostic value of plasma neurofilament light.
Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, Benedet AL, Pascoal TA, Lleó A, Parnetti L, Galimberti D, Bonanni L, Pilotto A, Padovani A, Lycke J, Novakova L, Axelsson M, Velayudhan L, Rabinovici GD, Miller B, Pariante C, Nikkheslat N, Resnick SM, Thambisetty M, Schöll M, Fernández-Eulate G, Gil-Bea FJ, López de Munain A, Al-Chalabi A, Rosa-Neto P, Strydom A, Svenningsson P, Stomrud E, Santillo A, Aarsland D, van Swieten JC, Palmqvist S, Zetterberg H, Blennow K, Hye A, Hansson O. Nat Commun. 2021 Jun 7;12(1):3400. doi: 10.1038/s41467-021-23620-z.

Sex differences in off-target binding using tau positron emission tomography.
Smith R, Strandberg O, Leuzy A, Betthauser TJ, Johnson SC, Pereira JB, Hansson O. Neuroimage Clin. 2021;31:102708. doi: 10.1016/j.nicl.2021.102708. Epub 2021 May 29.

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.
Pereira JB, Janelidze S, Stomrud E, Palmqvist S, van Westen D, Dage JL, Mattsson-Carlgren N, Hansson O. Brain. 2021 Oct 22;144(9):2826-2836. doi: 10.1093/brain/awab163.

The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.
Franzmeier N, Ossenkoppele R, Brendel M, Rubinski A, Smith R, Kumar A, Mattsson-Carlgren N, Strandberg O, Duering M, Buerger K, Dichgans M, Hansson O, Ewers M;  Alzheimer’s Disease Neuroimaging Initiative (ADNI)* and the Swedish BioFINDER study.Alzheimers Dement. 2021 Jun 1. doi: 10.1002/alz.12371. Online ahead of print.

A multicenter comparison of [¹⁸F]flortaucipir, [¹⁸F]RO948, and [¹⁸F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.
Leuzy A, Pascoal TA, Strandberg O, Insel P, Smith R, Mattsson-Carlgren N, Benedet AL, Cho H, Lyoo CH, La Joie R, Rabinovici GD, Ossenkoppele R, Rosa-Neto P, Hansson O. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2295-2305. doi: 10.1007/s00259-021-05401-4. Epub 2021 May 27.

Health utility in preclinical and prodromal Alzheimer’s disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study.
Gustavsson A, Raket LL, Lilja M, Rutten-Jacobs L, Fues Wahl H, Bagijn M, Stomrud E, Hansson O, Palmqvist S. Alzheimers Dement. 2021 Nov;17(11):1832-1842. doi: 10.1002/alz.12355. Epub 2021 May 13.

Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.
Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, Reiman EM, Palmqvist S, Dage JL, Beach TG, Hansson O. EMBO Mol Med. 2021 Jun 7;13(6):e14022. doi: 10.15252/emmm.202114022. Epub 2021 May 5.PMID: 33949133 Free PMC article.

Four distinct trajectories of tau deposition identified in Alzheimer’s disease.
Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, Strandberg OT, La Joie R, Aksman LM, Grothe MJ, Iturria-Medina Y; Alzheimer’s Disease Neuroimaging Initiative, Pontecorvo MJ, Devous MD, Rabinovici GD, Alexander DC, Lyoo CH, Evans AC, Hansson O. Nat Med. 2021 May;27(5):871-881. doi: 10.1038/s41591-021-01309-6. Epub 2021 Apr 29.

Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson’s disease.
Owens-Walton C, Jakabek D, Power BD, Walterfang M, Hall S, van Westen D, Looi JCL, Shaw M, Hansson O. Psychiatry Res Neuroimaging. 2021 Jun 30;312:111273. doi: 10.1016/j.pscychresns.2021.111273.

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias.
Cicognola C, Hansson O, Scheltens P, Kvartsberg H, Zetterberg H, Teunissen CE, Blennow K. Alzheimers Res Ther. 2021 Feb 8;13(1):38. doi: 10.1186/s13195-020-00756-6.

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K; Alzheimer’s Disease Neuroimaging Initiative, Dage JL, Stomrud E, Janelidze S, Mattsson-Carlgren N, Hansson O. Nat Med. 2021 Jun;27(6):1034-1042. 

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H, Blennow K, Reiman EM, Stomrud E, Dage JL, Hansson O. Nat Med. 2020 Mar;26(3):379-386

Early stages of tau pathology and its associations with functional connectivity,
atrophy and memory.
Berron D, Vogel JW, Insel PS, Pereira JB, Xie L, Wisse LEM, Yushkevich PA, Palmqvist S,
Mattsson-Carlgren N, Stomrud E, Smith R, Strandberg O, Hansson O. Brain. 2021 Mar
16:awab114.

Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid,
tau, and cognition.
Cullen NC, Mälarstig AN, Stomrud E, Hansson O, Mattsson-Carlgren N. Sci Rep. 2021
Jan 21;11(1):1965.

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s
disease.
Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, Mattsson-
Carlgren N, Schöll M, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H,
Lovestone S, Aarsland D; AddNeuroMed consortium, Hansson O, Rosa-Neto P,
Westman E, Blennow K, Zetterberg H, Ashton NJ.  Alzheimers Dement. 2021 Jan 25. Online ahead of print.

Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s
disease.
Johansson M, Stomrud E, Insel PS, Leuzy A, Johansson PM, Smith R, Ismail Z, Janelidze
S, Palmqvist S, van Westen D, Mattsson-Carlgren N, Hansson O. Transl Psychiatry.
2021 Jan 26;11(1):76.

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for
synaptic biomarkers.
Camporesi E, Lashley T, Gobom J, Lantero-Rodriguez J, Hansson O, Zetterberg H,
Blennow K, Becker B. Acta Neuropathol Commun. 2021 Feb 1;9(1):19.

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective
cognitive decline and other dementias.
Cicognola C, Hansson O, Scheltens P, Kvartsberg H, Zetterberg H, Teunissen CE,
Blennow K. Alzheimers Res Ther. 2021 Feb 8;13(1):38.

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future
conversion to Alzheimer dementia in patients with mild cognitive impairment.
Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren
N, Hansson O. Alzheimers Res Ther. 2021 Mar 27;13(1):68.

A multisite analysis of the concordance between visual image interpretation and
quantitative analysis of [18F]flutemetamol amyloid PET images.
Bucci M, Savitcheva I, Farrar G, Salvadó G, Collij L, Doré V, Gispert JD, Gunn R,
Hanseeuw B, Hansson O, Shekari M, Lhommel R, Molinuevo JL, Rowe C, Sur C,
Whittington A, Buckley C, Nordberg A. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2183-2199

Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s
disease.
Singleton E, Hansson O, Pijnenburg YAL, La Joie R, Mantyh WG, Tideman P, Stomrud
E, Leuzy A, Johansson M, Strandberg O, Smith R, Berendrecht E, Miller BL, Iaccarino L,
Edwards L, Strom A, Wolters EE, Coomans E, Visser D, Golla SSV, Tuncel H, Bouwman
F, Van Swieten JC, Papma JM, van Berckel B, Scheltens P, Dijkstra AA, Rabinovici GD,
Ossenkoppele R. J Neurol Neurosurg Psychiatry. 2021 Apr 13:jnnp-2020-325497.

Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson’s disease.
Owens-Walton C, Jakabek D, Power BD, Walterfang M, Hall S, van Westen D, Looi JCL,
Shaw M, Hansson O. Psychiatry Res Neuroimaging. 2021 Apr 8;312:111273.

Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease. Gertje EC, van Westen D, Panizo C, Mattsson-Carlgren N, Hansson O. Neurology. 2021 Jan 12;96(2):e193-e202.

Biomarker testing in MCI patients-deciding who to test. van Maurik IS, Rhodius-Meester HFM, Teunissen CE, Scheltens P, Barkhof F, Palmqvist S, Hansson O, van der Flier WM, Berkhof J. Alzheimers Res Ther. 2021 Jan 7;13(1):14. 

Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. Provost K, Iaccarino L, Soleimani-Meigooni DN, Baker S, Edwards L, Eichenlaub U, Hansson O, Jagust W, Janabi M, La Joie R, Lesman-Segev O, Mellinger TJ, Miller BL, Ossenkoppele R, Pham J, Smith R, Sonni I, Strom A, Mattsson-Carlgren N, Rabinovici GD; Alzheimer’s Disease Neuroimaging Initiative (ADNI).Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2259-2271

2020

Pre-analytical protocol for measuring Alzheimer’s disease biomarkers in fresh CSF. Hansson O, Rutz S, Zetterberg H, Bauer E, Hähl T, Manuilova E, Mert MC, Wahl S, Blennow K, Stomrud E. Alzheimers Dement (Amst). 2020 Dec 18;12(1):e12137.

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Mattsson-Carlgren N, Palmqvist S, Blennow K, Hansson O. Nat Commun. 2020 Dec 7;11(1):6252

Plasma Phospho-Tau Identifies Alzheimer’s Co-Pathology in Patients with Lewy Body Disease. Hall S, Janelidze S, Londos E, Leuzy A, Stomrud E, Dage JL, Hansson O. Mov Disord. 2021 Mar;36(3):767-771

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease. Pereira JB, Janelidze S, Ossenkoppele R, Kvartsberg H, Brinkmalm A, Mattsson-Carlgren N, Stomrud E, Smith R, Zetterberg H, Blennow K, Hansson O. Brain. 2021 Feb 12;144(1):310-324

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease. Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, Mengel D, Walsh DM, Stomrud E, Dage JL, Hansson O. Brain. 2020 Dec 5;143(11):3234-3241.

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Smith R, Strandberg O, Mattsson-Carlgren N, Leuzy A, Palmqvist S, Pontecorvo MJ, Devous MD, Ossenkoppele R, Hansson O. Brain. 2020 Dec 1;143(12):3805-3815. 

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Hanes J, Kovac A, Kvartsberg H, Kontsekova E, Fialova L, Katina S, Kovacech B, Stevens E, Hort J, Vyhnalek M, Boonkamp L, Novak M, Zetterberg H, Hansson O, Scheltens P, Blennow K, Teunissen CE, Zilka N. Neurology. 2020 Dec 1;95(22):e3026-e3035.

Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease. Franzmeier N, Dewenter A, Frontzkowski L, Dichgans M, Rubinski A, Neitzel J, Smith R, Strandberg O, Ossenkoppele R, Buerger K, Duering M, Hansson O, Ewers M. Sci Adv. 2020 Nov 27;6(48)

Plasma NT1 Tau is a Specific and Early Marker of Alzheimer’s Disease. Mengel D, Janelidze S, Glynn RJ, Liu W, Hansson O, Walsh DM. Ann Neurol. 2020 Nov;88(5):878-892.

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease. Andersson E, Janelidze S, Lampinen B, Nilsson M, Leuzy A, Stomrud E, Blennow K, Zetterberg H, Hansson O. Neurobiol Aging. 2020 Nov;95:143-153.

Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load. Leuzy A, Lilja J, Buckley CJ, Ossenkoppele R, Palmqvist S, Battle M, Farrar G, Thal DR, Janelidze S, Stomrud E, Strandberg O, Smith R, Hansson O. Neurology. 2020 Nov 24;95(21):e2834-e2844.

The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Ossenkoppele R, Leuzy A, Cho H, Sudre CH, Strandberg O, Smith R, Palmqvist S, Mattsson-Carlgren N, Olsson T, Jögi J, Stormrud E, Ryu YH, Choi JY; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD research group, Boxer AL, Gorno-Tempini ML, Miller BL, Soleimani-Meigooni D, Iaccarino L, La Joie R, Borroni E, Klein G, Pontecorvo MJ, Devous MD Sr, Villeneuve S, Lyoo CH, Rabinovici GD, Hansson O. Eur J Nucl Med Mol Imaging. 2020 Nov 19.2021 Jul;48(7):2245-2258

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, Stomrud E, Palmqvist S, Mattsson-Carlgren N, Hansson O. JAMA Neurol. 2020 Nov 9:e204201.

Acute phase markers in CSF reveal inflammatory changes in Alzheimer’s disease that intersect with pathology, APOE ε4, sex and age. Ayton S, Janelidze S, Roberts B, Palmqvist S, Kalinowski P, Diouf I, Belaidi AA, Stomrud E, Bush AI, Hansson O. Prog Neurobiol. 2020 Aug 31:101904.

Image reconstruction methods affect software-aided assessment of pathologies of [¹⁸F]flutemetamol and [¹⁸F]FDG brain-PET examinations in patients with neurodegenerative diseases. Lindström E, Oddstig J, Danfors T, Jögi J, Hansson O, Lubberink M. Neuroimage Clin. 2020;28:102386.

Validation of a spatial normalization method using a principal component derived adaptive template for [¹⁸F]florbetaben PET. Leuzy A, Heurling K, De Santi S, Bullich S, Hansson O, Lilja J. Am J Nucl Med Mol Imaging. 2020 Aug 25;10(4):161-167. eCollection 2020.

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. Palmqvist S, Janelidze S, Quiroz YT,  Zetterberg H, Lopera F, Stomrud E,  Su Y, Chen Y, Serrano GE, Leuzy A, Mattsson-Carlgren N, Strandberg O, Smith R,  Villegas A, Sepulveda-Falla D, Chai X, Proctor NK, Beach TG, Blennow K, Dage JL, Reiman EM, Hansson O. JAMA. 2020;324(8):772-781

Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up. Mårtensson G, Håkansson C, Pereira JB, Palmqvist S, Hansson O, van Westen D, Westman E. Neuroimage Clin. 2020 Jun 10;27:102310.

The effects of tau, amyloid and white matter lesions on mobility, dual tasking and balance in older people. Nilsson MH, Tangen GG, Palmqvist S, van Westen D, Mattsson-Carlgren N, Stomrud E, Hansson O. J Gerontol A Biol Sci Med Sci. 2020 Jun 7:glaa143.

Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease. Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC, Hansson O; Alzheimer’s Disease Neuroimaging Initiative; Swedish BioFinder Study. Nat Commun. 2020 May 26;11(1):2612.

Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. Idland AV, Sala-Llonch R, Watne LO, Brækhus A, Hansson O, Blennow K, Zetterberg H, Sørensen Ø, Walhovd KB, Wyller TB, Fjell AM. Neurobiol Aging. 2020 Sep;93:1-15.

CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers. Ahmad S, Milan MDC, Hansson O, Demirkan A, Agustin R, Sáez ME, Giagtzoglou N, Cabrera-Socorro A, Bakker MHM, Ramirez A, Hankemeier T, Stomrud E, Mattsson-Carlgren N, Scheltens P, van der Flier WM, Ikram MA, Malarstig A, Teunissen CE, Amin N, van Duijn CM. Sci Rep. 2020 May 19;10(1):8233.

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease. Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, Zetterberg H, Rosen HJ, Rabinovici G, Chai X, Blennow K, Dage JL, Stomrud E, Smith R, Palmqvist S, Hansson O. Sci Adv. 2020 Apr 15;6(16):eaaz2387.

The implications of different approaches to define AT(N) in Alzheimer disease. Mattsson-Carlgren N, Leuzy A, Janelidze S, Palmqvist S, Stomrud E, Strandberg O, Smith R,Hansson O. Neurology. 2020 May 26;94(21):e2233-e2244

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, Ohlsson T, Jögi J, Palmqvist S, Mattsson-Carlgren N, Strandberg O, Stomrud E, Hansson O. JAMA Neurol. 2020 May 11:e200989.

Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, Schöll M, Massarweh G, Soucy JP, Höglund K, Brinkmalm G, Mattsson N, Palmqvist S, Gauthier S, Stomrud E, Zetterberg H, Hansson O, Rosa-Neto P, Blennow K. Lancet Neurol. 2020 May;19(5):422-433.

Relationship between cortical iron and tau aggregation in Alzheimer’s disease. Spotorno N, Acosta-Cabronero J, Stomrud E, Lampinen B, Strandberg OT, van Westen D, Hansson O. Brain. 2020 May 1;143(5):1341-1349.

Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease. Berron D, van Westen D, Ossenkoppele R, Strandberg O, Hansson O. Brain. 2020 Apr 1;143(4):1233-1248.

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, Proctor NK, Chai X, Shcherbinin S, Sims JR, Triana-Baltzer G, Theunis C, Slemmon R, Mercken M, Kolb H, Dage JL,Hansson O. Nat Commun. 2020 Apr 3;11(1):1683.

The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. Borland E, Stomrud E, van Westen D, Hansson O, Palmqvist S. Alzheimers Res Ther. 2020 Mar 24;12(1):30.

Towards unconstrained compartment modeling in white matter using diffusion-relaxation MRI with tensor-valued diffusion encoding. Lampinen B, Szczepankiewicz F, Mårtensson J, van Westen D, Hansson O, Westin CF, Nilsson M. Reson Med. 2020 Sep;84(3):1605-1623.

Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson’s disease. Pereira JB, Hall S, Jalakas M, Grothe MJ, Strandberg O, Stomrud E, Westman E, van Westen D, Hansson O. Neurobiol Dis. 2020 Mar 4, 2020-06-01, Volume 139, Article 104831

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia.
Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H, Blennow K, Reiman EM, Stomrud E, Dage JL, Hansson O.
Nat Med. 26, 379-386(2020)

Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease.
Ossenkoppele R, Lyoo CH, Jester-Broms J, Sudre CH, Cho H, Ryu YH, Choi JY, Smith R, Strandberg O, Palmqvist S, Kramer J, Boxer AL, Gorno-Tempini ML, Miller BL, La Joie R, Rabinovici GD, Hansson O. JAMA Neurol. 2020 May; 77(5): 1–11.

[18F]Flortaucipir Distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case. Smith R, Pawlik D, Nilsson CF, Englund E, Hansson O     Acta Neuropathol 2020 Feb;139(2):411-413.

Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease.
Ossenkoppele R, Lyoo CH, Sudre CH, van Westen D, Cho H, Ryu YH, Choi JY, Smith R, Strandberg O, Palmqvist S, Westman E, Tsai R, Kramer J, Boxer AL, Gorno-Tempini ML, La Joie R, Miller BL, Rabinovici GD, Hansson O. Alzheimers Dement. 2020 Feb;16(2):335-344.

Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. Höglund K, Schussler N, Kvartsberg H, Smailovic U, Brinkmalm G, Liman V, Becker B, Zetterberg H, Cedazo-Minguez A, Janelidze S, Lefevre IA, Eyquem S, Hansson O, Blennow K. Neurobiol Dis. 2020 Feb;134:104645.

Head-to-head comparison of tau positron emission tomography tracers  [¹⁸F]flortaucipir and [¹⁸F]RO948.   Smith R, Schöll M, Leuzy A, Jögi J, Ohlsson T, Strandberg O, Hansson O.   Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):342-354.

Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia.
Gustavsson AM, van Westen D, Stomrud E, Engström G, Nägga K, Hansson O.
Ann Neurol. 2020 Jan;87(1):52-62.

Apathy and anxiety are early markers of Alzheimer’s disease.
Johansson M, Stomrud E, Lindberg O, Westman E, Johansson PM, van Westen D, Mattsson N, Hansson O. Neurobiol Aging. 2020 Jan;85:74-82.

Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease. Franzmeier N, Neitzel J, Rubinski A, Smith R, Strandberg O, Ossenkoppele R, Hansson O, Ewers M. Alzheimer’s Disease Neuroimaging Initiative (ADNI). Nat Commun. 2020 Jan 17;11(1):347. 

 

2019

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume. Caldwell JZK, Cummings JL, Banks SJ, Palmqvist S, Hansson O. Alzheimers Res Ther. 2019 Dec 26;11(1):109.

Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders. Hall S, Janelidze S, Zetterberg H, Brix B, Mattsson N, Surova Y, Blennow K, Hansson O.
Mov Disord. 2020 Mar;35(3):513-518.

Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies. Spotorno N, Hall S, Irwin DJ, Rumetshofer T, Acosta-Cabronero J, Deik AF, Spindler MA, Lee EB, Trojanowski JQ, van Westen D, Nilsson M, Grossman M, Nestor PJ, McMillan CT, Hansson O. Radiology. 2019 Dec;293(3):646-653.

Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. Pereira JB, Ossenkoppele R, Palmqvist S, Strandberg TO, Smith R, Westman E, Hansson O. Elife. 2019 Dec 9;8:e50830.

Predicting Clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays. Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K, Wahl S, Eichenlaub U, Lifke V, Simon M, Trojanowski JQ, Hansson O. Sci Rep. 2019 Dec 13;9(1):19024.        

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease.Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, Eichenlaub U, Dage JL, Chai X, Blennow K, Mattsson N, Hansson O.
EMBO Mol Med. 2019 Dec;11(12):e11170.

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease. Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S, Stomrud E, Lee J, Fitz L, Samad TA, Ramaswamy G, Margolin RA, Malarstig A, Hansson O.
Acta Neuropathol Commun. 2019 Nov 6;7(1):169.

A quick test of cognitive speed can predict development of dementia in Parkinson’s disease. Jalakas M, Palmqvist S, Hall S, Svärd D, Lindberg O, Pereira JB, van Westen D, Hansson O. Sci Rep. 2019 Oct 28;9(1):15417.

Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid. Frankel R, Törnquist M, Meisl G, Hansson O, Andreasson U, Zetterberg H, Blennow K, Frohm B, Cedervall T, Knowles TPJ, Leiding T, Linse S. Commun Biol. 2019 Oct 8;2:365.

Alzheimer’s Disease Neuroimaging Initiative. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.  van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Frisoni GB, Spiru L, Freund-Levi Y, Wallin AK, Hampel H, Soininen H, Tsolaki M, Verhey F, Kłoszewska I, Mecocci P, Vellas B, Lovestone S, Galluzzi S, Herukka SK, Santana I, Baldeiras I, de Mendonça A, Silva D, Chetelat G, Egret S, Palmqvist S, Hansson O, Visser PJ, Berkhof J, van der Flier WM. Lancet Neurol. 2019 Nov;18(11):1034-1044

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease. Sjödin S, Brinkmalm G, Öhrfelt A, Parnetti L, Paciotti S, Hansson O, Hardy J, Blennow K, Zetterberg H, Brinkmalm A. Alzheimers Res Ther. 2019 Sep 14;11(1):82

Increased functional connectivity of thalamic subdivisions in patients with Parkinson’s disease. Owens-Walton C, Jakabek D, Power BD, Walterfang M, Velakoulis D, van Westen D, Looi JCL, Shaw M, Hansson O. PLoS One. 2019 Sep 4;14(9):e0222002. 

β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly.  Svenningsson AL, Stomrud E, Insel PS, Mattsson N, Palmqvist S, Hansson O. Sci Rep. 2019 Aug 1;9(1):11180. 

α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson’s disease patients.  Paslawski W, Zareba-Paslawska J, Zhang X, Hölzl K, Wadensten H, Shariatgorji M, Janelidze S, Hansson O, Forsgren L, Andrén PE, Svenningsson P. Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15226-15235. 

Determining clinically meaningful decline in preclinical Alzheimer disease. Insel PS, Weiner M, Mackin RS, Mormino E, Lim YY, Stomrud E, Palmqvist S, Masters CL, Maruff PT, Hansson O, Mattsson N. Neurology. 2019 Jul 23;93(4):e322-e333.

Towards a unified protocol for handling of CSF before β-amyloid measurements. Janelidze S, Stomrud E, Brix B, Hansson O. Alzheimers Res Ther. 2019 Jul 19;11(1):63. 

Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O. JAMA Neurol. 2019 Jul 17;76(11)

Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. Puschmann A, Jiménez-Ferrer I, Lundblad-Andersson E, Mårtensson E, Hansson O, Odin P, Widner H, Brolin K, Mzezewa R, Kristensen J, Soller M, Rödström EY, Ross OA, Toft M, Breedveld GJ, Bonifati V, Brodin L, Zettergren A, Sydow O, Linder J, Wirdefeldt K, Svenningsson P, Nissbrandt H, Belin AC, Forsgren L, Swanberg M. Parkinsonism Relat Disord. 2019 Sep 6. 

European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND). Düzel E, Acosta-Cabronero J, Berron D, Biessels GJ, Björkman-Burtscher I, Bottlaender M, Bowtell R, Buchem MV, Cardenas-Blanco A, Boumezbeur F, Chan D, Clare S, Costagli M, de Rochefort L, Fillmer A, Gowland P, Hansson O, Hendrikse J, Kraff O, Ladd ME, Ronen I, Petersen E, Rowe JB, Siebner H, Stoecker T, Straub S, Tosetti M, Uludag K, Vignaud A, Zwanenburg J, Speck O. Alzheimers Dement (Amst). 2019 Jul 31;11:538-549. 

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, Bittner T, Mattsson N, Eichenlaub U, Blennow K, Hansson O. JAMA Neurol. 2019 Sep; 76(9): 1060–1069

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease. Schultz N, Janelidze S, Byman E, Minthon L, Nägga K, Hansson O, Wennström M. PLoS One. 2019 Jun 17;14(6):e0218561.

Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. Sjöström H, Surova Y, Nilsson M, Granberg T, Westman E, van Westen D, Svenningsson P, Hansson O. Sci Rep. 2019 Apr 15;9(1):6079. 

Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. Hahn A, Strandberg TO, Stomrud E, Nilsson M, van Westen D, Palmqvist S, Ossenkoppele R, Hansson O. Cereb Cortex. 2019 May 1;29(5):2173-2182

Searching for the neurite density with diffusion MRI: Challenges for biophysical modeling. Lampinen B, Szczepankiewicz F, Novén M, van Westen D, Hansson O, Englund E, Mårtensson J, Westin CF, Nilsson M. Hum Brain Mapp. 2019 Jun 1;40(8):2529-2545.

Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline. Håkansson C, Torisson G, Londos E, Hansson O, van Westen D. Neuroradiology. 2019 Apr;61(4):397-404. 

Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer’s Disease. Minta K, Portelius E, Janelidze S, Hansson O, Zetterberg H, Blennow K, Andreasson U. J Alzheimers Dis. 2019;69(4):1213-1220

CSF placental growth factor – a novel candidate biomarker of frontotemporal dementia. Hansson O, Santillo AF, Meeter LH, Nilsson K, Landqvist Waldö M, Nilsson C, Blennow K, van Swieten JC, Janelidze S. Ann Clin Transl Neurol. 2019 Mar 29;6(5):863-872.

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer’s disease: Cross-validation study of practical algorithms.  Palmqvist S, Insel PS, Zetterberg H, Blennow K, Brix B, Stomrud E; Alzheimer’s Disease Neuroimaging Initiative; Swedish BioFINDER study, Mattsson N, Hansson O. Alzheimers Dement. 2019 Feb;15(2):194-204. 

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. Zettergren A, Höglund K, Kern S, Thorvaldsson V, Johan Skoog M, Hansson O, Andreasen N, Bogdanovic N, Blennow K, Skoog I, Zetterberg H. Sci Rep. 2019 Feb 21;9(1):2460.

Data-driven approaches for tau-PET imaging biomarkers in Alzheimer’s disease. Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R; Alzheimer’s Disease Neuroimaging Initiative; Swedish BioFINDER Study. Hum Brain Mapp. 2019 Feb 1;40(2):638-651. 

Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer’s disease. Mattsson N, Insel PS, Donohue M, Jögi J, Ossenkoppele R, Olsson T, Schöll M, Smith R, Hansson O. Alzheimers Dement. 2019 Apr;15(4):570-580. 

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, Palmqvist S, Hansson O. Neurology. 2019 Feb 5;92(6):e601-e612. 

Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study. Voevodskaya O, Poulakis K, Sundgren P, van Westen D, Palmqvist S, Wahlund LO, Stomrud E, Hansson O, Westman E; Swedish BioFINDER Study Group. Neurology. 2019 Jan 29; 92(5): e395–e405

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease. Cicognola C, Brinkmalm G, Wahlgren J, Portelius E, Gobom J, Cullen NC, Hansson O, Parnetti L, Constantinescu R, Wildsmith K, Chen HH, Beach TG, Lashley T, Zetterberg H, Blennow K, Höglund K. Acta Neuropathol. 2019 Feb;137(2):279-296. 

2018

Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology. Smith R, Wibom M, Pawlik D, Englund E, Hansson O. JAMA Neurol. 2019 Mar; 76(3): 310–31

Exploring causality of the association between smoking and Parkinson’s disease. Gallo V, Vineis P, Cancellieri M, Chiodini P, Barker RA, Brayne C, Pearce N, Vermeulen R, Panico S, Bueno-de-Mesquita B, Vanacore N, Forsgren L, Ramat S, Ardanaz E, Arriola L, Peterson J, Hansson O, Gavrila D, Sacerdote C, Sieri S, Kühn T, Katzke VA, van der Schouw YT, Kyrozis A, Masala G, Mattiello A, Perneczky R, Middleton L, Saracci R, Riboli E.  Int J Epidemiol. 2019 Jun; 48(3): 912–925.

Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer’s disease.Mattsson N, Eriksson O, Lindberg O, Schöll M, Lampinen B, Nilsson M, Insel PS, Lautner R, Strandberg O, van Westen D, Zetterberg H, Blennow K, Palmqvist S, Stomrud E, Hansson O. Neurobiol Aging. 2018 Nov;71:81-90.

Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.  Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, Pijnenburg Y, Keulen MA, Groot C, van Berckel BNM, van der Flier WM, Scheltens P, Rohrer JD, Warren JD, Schott JM, Fox NC, Sanchez-Valle R, Grau-Rivera O, Gelpi E, Seelaar H, Papma JM, van Swieten JC, Hodges JR, Leyton CE, Piguet O, Rogalsky EJ, Mesulam MM, Koric L, Nora K, Pariente J, Dickerson B, Mackenzie IR, Hsiung GR, Belliard S, Irwin DJ, Wolk DA, Grossman M, Jones M, Harris J, Mann D, Snowden JS, Chrem-Mendez P, Calandri IL, Amengual AA, Miguet-Alfonsi C, Magnin E, Magnani G, Santangelo R, Deramecourt V, Pasquier F, Mattsson N, Nilsson C, Hansson O, Keith J, Masellis M, Black SE, Matías-Guiu JA, Cabrera-Martin MN, Paquet C, Dumuirger J, Teichmann M, Sarazin M, Bottlaender M, Dubois B, Rowe CC, Villemagne VL, Vandenberghe R, Granadillo E, Teng E, Mendez M, Meyer PT, Frings L, Lleó A, Blesa R, Fortea J, Seo SW, Diehl-Schmid J, Grimmer T, Frederiksen KS, Sánchez-Juan P, Chételat G, Jansen W, Bouchard RW, Robert L Jr, Visser PJ, Ossenkoppele R. Ann Neurol. 2018 Nov;84(5):729-740.

Parkinson’s disease: evolution of cognitive impairment and CSF Aβ_1-42 profiles in a prospective longitudinal study.  Lerche S, Wurster I, Röben B, Machetanz G, Zimmermann M, Bernhard F, Stransky E, Deuschle C, Schulte C, Hansson O, Zetterberg H, Gasser T, Berg D, Maetzler W, Brockmann K. J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):165-170.

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.  Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O, Palmqvist S, Mattsson N, Janelidze S, Santillo A, Ohlsson T, Jögi J, Tsai R, La Joie R, Kramer J, Boxer AL, Gorno-Tempini ML, Miller BL, Choi JY, Ryu YH, Lyoo CH, Hansson O. JAMA. 2018 Sep 18;320(11):1151-1162.

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders. Hall S, Janelidze S, Surova Y, Widner H, Zetterberg H, Hansson O. Sci Rep. 2018 Sep 5;8(1):13276.

Molecular properties underlying regional vulnerability to Alzheimer’s disease pathology.  Grothe MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, Schöll M, Hansson O, Teipel SJ; Alzheimer’s Disease Neuroimaging Initiative. Brain. 2018 Sep 1;141(9):2755-2771.

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study. Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T, Jögi J, Palmqvist S, Stomrud E, Hansson O. Alzheimers Res Ther. 2018 Aug 7;10(1):77.

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, Blennow K, Hansson O. Neurology. 2018 Aug 28;91(9):e867-e877. 

Regional times to equilibria and their impact on semi-quantification of [₁₈F]AV-1451 uptake. Heurling K, Smith R, Strandberg OT, Schain M, Ohlsson T, Hansson O, Schöll M. J Cereb Blood Flow Metab. 2018 Aug 3:271678X18791430. 

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer’s disease diagnosis: A Review.  Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H, Vanderstichele H, Molinuevo JL, Shaw LM, Vandijck M, Verbeek MM, Savage M, Mattsson N, Lewczuk P, Batrla R, Rutz S, Dean RA, Blennow K. Alzheimers Dement. 2018-10-01, Volume 14, Issue 10, Pages 1313-133. 

Is longitudinal tau PET ready for use in Alzheimer’s disease clinical trials?  Hansson O, Mormino EC. Brain. 2018 May 1;141(5):1241-1244.

Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic Review. Ygland E, van Westen D, Englund E, Rademakers R, Wszolek ZK, Nilsson K, Nilsson C, Landqvist Waldö M, Alafuzoff I, Hansson O, Gustafson L, Puschmann A.Alzheimers Res Ther. 2018 Jan 9;10(1):2.

Alzheimer’s Disease Neuroimaging Initiative. Amyloid pathology in the progression to mild cognitive impairment. Insel PS, Hansson O, Mackin RS, Weiner M, Mattsson N. Neurobiol Aging. 2018 Apr;64:76-84.

Altered structural network organization in cognitively normal individuals with amyloid pathology. Voevodskaya O, Pereira JB, Volpe G, Lindberg O, Stomrud E, van Westen D, Westman E, Hansson O. Neurobiol Aging. 2018 Apr;64:15-24..

Comparing 18F-AV-1451 with CSF T-tau and P-tau for diagnosis of Alzheimer’s disease. Mattsson N, Smith R, Strandberg O, Palmqvist S, Schöll M, Insel P, Hagerstrom D, Olsson T, Zetterberg H, Blennow K, Jögi J, Hansson O. Neurology. 2018 Jan 30;90(5):e388-e395.

Amyloid network topology characterizes the progression of Alzheimer’s disease during the pre-dementia stages. Pereira JB, Strandberg TO, Palmqvist S, Volpe G, Westen Dv, Westman E, Hansson O, for the Alzheimer’s Disease Neuroimaging Initiative. Cerebral Cortex.  2018 Jan 1;28(1):340-349.

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A,  Engelborghs S, Na DL, Chételat G, Molinuevo JL, Landau SM, Mattsson N, Kornhuber  J, Sabri O, Rowe CC, Parnetti L, Popp J, Fladby T, Jagust WJ, Aalten P, Lee DY,  Vandenberghe R, Resende de Oliveira C, Kapaki E, Froelich L, Ivanoiu A,  Gabryelewicz T, Verbeek MM, Sanchez-Juan P, Hildebrandt H, Camus V, Zboch M,  Brooks DJ, Drzezga A, Rinne JO, Newberg A, de Mendonça A, Sarazin M, Rabinovici  GD, Madsen K, Kramberger MG, Nordberg A, Mok V, Mroczko B, Wolk DA, Meyer PT,  Tsolaki M, Scheltens P, Verhey FRJ, Visser PJ; Amyloid Biomarker Study Group,
Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel  H, van Berckel BNM, Blennow K, van Buchem MA, Cavedo E, Chen K, Chipi E, Cohen  AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gkatzima O, Gordon MF,  Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Johannsen P,  Klimkowicz-Mrowiec A, Köhler S, Koglin N, van Laere K, de Leon M, Lisetti V,  Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Nordlund A, Novak  GP, Paraskevas GP, Perera G, Peters O, Ramakers IHGB, Rami L, Rodríguez-Rodríguez
E, Roe CM, Rot U, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L,  Stomrud E, Struyfs H, Teunissen CE, Vos SJB, van Waalwijk van Doorn LJC, Waldemar  G, Wallin ÅK, Wiltfang J, Zetterberg H. JAMA   Psychiatry. 2018 Jan 1;75(1):84-95. 

Amyloid Network Topology Characterizes the Progression of Alzheimer’s Disease During the Predementia Stages.Pereira JB, Strandberg TO, Palmqvist S, Volpe G, van Westen D, Westman E, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Cereb Cortex. 2018 Jan 1;28(1):340-349.

Amyloid blood biomarker detects Alzheimer’s disease. Nabers A, Perna L, Lange J, Mons U, Schartner J, Güldenhaupt J, Saum KU, Janelidze S, Holleczek B, Rujescu D, Hansson O, Gerwert K, Brenner H. EMBO Mol Med. 2018 May;10(5). pii:e8763.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer’s disease. Mattsson N, Groot C, Jansen WJ, Landau S, Villemagne V, Engelborghs S, Mintun M, Lleo A, Molinuevo JL, Jagust W, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimella R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem  MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi  Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere  K, de Leon M, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC,  Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe  CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E,  Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC,  Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC,  Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL,  Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM,  Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier  WM, Scheltens P, Visser PJ, Ossenkoppele R.  Alzheimers Dement. 2018-07-01, Volume 14, Issue 7, Pages 913-92

Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms. Owens-Walton C, Jakabek D, Li X, Wilkes FA, Walterfang M, Velakoulis D, van Westen D, Looi JCL, Hansson O. Psychiatry Res. 2018 May 30;275:5-13

18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies.  Smith R, Schöll M, Londos E, Ohlsson T, Hansson O.
Sci Rep. 2018 Mar 16;8(1):4717. 

CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke, V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw LM; Swedish BioFINDER study group; Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement. 2018-11-01, Volume 14, Issue 11, Pages 1470-1481

Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease. Patra K, Soosaipillai A, Sando SB, Lauridsen C, Berge G, Møller I, Grøntvedt  GR, Bråthen G, Begcevic I, Moussaud S, Minthon L, Hansson O, Diamandis EP, White  LR, Nielsen HM.  Alzheimers Res Ther. 2018 Jan 29;10(1):9. 

Alteration of putaminal fractional anisotropy in Parkinson’s disease: a longitudinal diffusion kurtosis imaging study. Surova Y, Nilsson M, Lampinen B, Lätt J, Hall S, Widner H, van Westen D, Hansson O. Neuroradiology. 2018  Mar;60(3):247-254. 

Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later Nägga K, Gustavsson AM, Stomrud E, Lindqvist D, van Westen D, Blennow K,  Zetterberg H, Melander O, Hansson O. Neurology. 2018 Jan  2;90(1):e73-e81. 

Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people. Hansson O, Palmqvist S, Ljung H, Cronberg T, van Westen D, Smith R. Alzheimers Dement. 2018 Jan;14(1):54-61.

2017

Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer’s Disease.Pereira JB, van Westen D, Stomrud E, Strandberg TO, Volpe G, Westman E,
Hansson O. Cereb Cortex. 2017 Oct 3:1-12.

The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer’s disease. Svärd D, Nilsson M, Lampinen B, Lätt J, Sundgren PC, Stomrud E, Minthon L, Hansson O, van Westen D. PLoS One. 2017 Sep 21;12(9):e0185239.  eCollection 2017.

A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease. Skillbäck T, Mattsson N, Hansson K, Mirgorodskaya E, Dahlén R, van der Flier W, Scheltens P, Duits F, Hansson O, Teunissen C, Blennow K, Zetterberg H, GobomJ.  Sci Rep. 2017 Oct 17;7(1):13333.

CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Skillbäck T, Delsing L, Synnergren J, Mattsson N, Janelidze S, Nägga K, Kilander L, Hicks R, Wimo A, Winblad B, Hansson O, Blennow K, Eriksdotter M, Zetterberg H. Neurobiol Aging. 2017 Nov;59:1-9. 

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations. Lautner R, Insel PS, Skillbäck T, Olsson B, Landén M, Frisoni GB, Herukka SK,  Hampel H, Wallin A, Minthon L, Hansson O, Blennow K, Mattsson N, Zetterberg H.  Alzheimers Res Ther. 2017 Oct 23;9(1):87.

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer’s Disease and Parkinsonian Disorders.  Sjödin S, Hansson O, Öhrfelt A, Brinkmalm G, Zetterberg H, Brinkmalm A, Blennow K. Proteomics Clin Appl. 2017  Dec;11(11-12). 

Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease. Pereira JB, Westman E, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Neurobiol Aging. 2017 Oct;58:14-29. 

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Palmqvist S, Schöll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, Blennow K, Landau S, Jagust W, Hansson O. Nature communications. 2017 Oct 31;8(1):1214.

Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, Hansson O.  JAMA Neurology 2017 Dec 1;74(12):1492-1501.

Atrophy of the posterior subiculum is associated with memory impairment, tau- and Aβ pathology in non-demented individuals. Lindberg O, Mårtensson G, Stomrud E, Palmqvist S, Wahlund L-O, Westman E, Hansson O. Frontiers in Aging Neuroscience. 2017 Sep 20;9:306.

In vivo retention of (18)F-AV-1451 in corticobasal syndrome. Smith R, Schöll M, Widner H, van Westen D, Svenningsson P, Hägerström D, Ohlsson T, Jögi J, Nilsson C, Hansson O. Neurology. 2017 Aug 22;89(8):845-853.

Distinct 18F-AV- 1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease. Schöll M, Ossenkoppele R, Strandberg O, Palmqvist S, Ohlsson T, Jögi J, Smith R, Hansson O. Brain 2017 Sep 1;140(9):2286-2294.

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease. Mattsson N, Schöll M, Strandberg O, Smith R, Palmqvist S, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Jögi J, Blennow K, Hansson O. EMBO Mol Med. 2017 Sep;9(9):1212-1223.

Plasma tau in Alzheimer disease   Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, Hanlon D, Song L, Shaw LM, Trojanowski JQ, Weiner MW, Hansson O, Blennow K   Neurology. 2016 Oct 25;87(17):1827-1835.

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Smith R, Puschmann A, Schöll M, Ohlsson T, van Swieten J, Honer M, Englund E, Hansson O. Brain. 2016 Sep;139(Pt 9):2372-9.

Reply: Do we still need positron emission tomography for early Alzheimer’s disease diagnosis? Palmqvist S, Mattsson N, Hansson O. Brain. 2016 Nov 1;139(11):e61. 

Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson’s Disease. Surova Y, Lampinen B, Nilsson M, Lätt J, Hall S, Widner H; Swedish BioFINDER study, van Westen D, Hansson O. PLoS One. 2016 Jun 30;11(6):e0157755.

Brain activity and Alzheimer’s disease: a complex relationship. Hansson O, Gouras G. Brain. 2016 Aug;139(Pt 8):2109-10.

Reference measurement procedure for CSF Aβ1-42 and the CSF Aβ1-42 /Aβ1-40 ratio – a cross-validation study against Amyloid PET. Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, Hansson O, Blennow K. J Neurochem. 2016 Nov;139(4):651-658

Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes. Vanderstichele HM, Janelidze S, Demeyer L, Coart E, Stoops E, Herbst V, Mauroo K, Brix B, Hansson O. J Alzheimers Dis. 2016 May 31;53(3):1121-32.

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease. Andersson CH, Hansson O, Minthon L, Andreasen N, Blennow K, Zetterberg H, Skoog I, Wallin A, Nilsson S, Kettunen P. J Alzheimers Dis. 2016 Jul 1;53(4):1353-63.

Plasma β-amyloid in Alzheimer’s disease and vascular disease. Janelidze S,  Stomrud E,  Palmqvist S,   Zetterberg H,  van Westen D,  Jeromin A,  Song L,  Hanlon D,  Tan Hehir C,  Baker D,  Blennow K,  Hansson O. Scientific Report. 2016 May 31;6:26801.

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer’s disease.
Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, Blennow K, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. EMBO Mol Med. 2016 Oct 4;8(10):1184-1196

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET. van Westen D, Lindqvist D, Blennow K, Minthon L, Nägga K, Stomrud E, Zetterberg H, Hansson O. Scientific Reports. 2016 Feb 9;6:20709.

Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer’s Disease Patient with Presenilin-1 Mutation. Smith R, Wibom M, Olsson T, Hägerström D, Jögi J, Rabinovici GD, Hansson O. J Alzheimers Dis. 2016 Jan 21;51(2):339-43.

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Palmqvist S, Mattsson N, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Brain. 2016 Apr;139(Pt 4):1226-36.

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson’s Disease. Hall S, Surova Y, Öhrfelt A; Swedish BioFINDER Study, Blennow K, Zetterberg H, Hansson O. Movement Disorders. 2016 Jun;31(6):898-905

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis. Mattsson N, Insel P, Palmqvist S, Stomrud E, van Westen D, Minthon L, Zetterberg H, Blennow K, Hansson O. Nature Communications. 2016 Mar 7;7:10918.

Early myo-inositol changes may precede Aβ pathology and relate to APOE genotype in Alzheimer disease. O Voevodskaya1, PC Sundgren, O Strandberg, H Zetterberg, L Minthon MD, K Blennow, L-O Wahlund, for the Swedish BioFINDER study group, E Westman and O Hansson. Neurology. 2016 May 10;86(19):1754-61.

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios improve the diagnostic accuracy for Alzheimer’s disease. S Janelidze, H Zetterberg, N Mattsson, S Palmqvist, H Vanderstichele, the Swedish BioFINDER study, O Lindberg, D van Westen, E Stomrud, L Minthon, K Blennow, O Hansson. Ann Clin Transl Neurol. 2016 Jan 1;3(3):154-65.

2015

Comparison of Amyloid PET and CSF Biomarkers for Identifying Early Alzheimer’s Disease.
Palmqvist S, Zetterberg H, Mattsson N, Johansson P, for the Alzheimer’s Disease Neuroimaging Initiative, Minthon M, Blennow K, Olsson M, for the Swedish BioFINDER study group, Hansson O. Neurology. 2015 Oct 6;85(14):1240-9.

Increased cerebrospinal fluid biomarkers of angiogenesis in Parkinson’s disease. Janelidze S, Lindqvist D, Francardo V, Hall S,Zetterberg H, Blennow K, Adler CH, Beach TG, Serrano GE, van Westen D, Londos E, the Swedish BioFINDER study, Cenci A, Hansson O. Neurology, 2015 Nov 24;85(21):1834-42.

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer’s disease: A prospective 9-year study. Stomrud E, Minthon L, Zetterberg H, Blennow K, Hansson O. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2015 1: 4, 403–411.

Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. Wennström M, Hall S, Nägga K, Londos E, Minthon L, Hansson O. Alzheimer’s Research & Therapy. 2015 Oct 5;7(1):63.

Extrapolation-Based References Improve Motion and Eddy-Current Correction of High B-Value DWI Data: Application in Parkinson’s Disease Dementia. Nilsson M, Szczepankiewicz F, van Westen D, Hansson O. PLoS One. 2015 Nov 3;10(11):e0141825

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease. Silajdzic E, Bjorkqvist M, & Hansson O. BMC Neurol 2015, 15:8.

Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects.
Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, Moghekar A, Albert M, Hu WT, Monge Argilés JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB, Linazasoro G, de Leon MJ, van der Flier WM, Scheltens P, Blennow K, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative. Brain. 2015 Sep;138(Pt 9):2701-15.

Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. Surova Y, Nilsson M, Lätt J, Lampinen B, Lindberg O, Hall S, Widner H, Nilsson C, van Westen D, Hansson O. Neuroradiology. 2015 Nov;57(11):1079-91.

Parkinson’s Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study. Gallo V, Brayne C, Forsgren L, Barker RA, Petersson J, Hansson O, Lindqvist D, Ruffmann C, Ishihara L, Luben R, Arriola L, Bergareche A, Gavrila D, Erro ME, Vanacore N, Sacerdote C, Bueno-de-Mesquita B, Vermeulen R, Seelen M, Sieri S, Masala G, Ramat S, Kyrozis A, Thricopolou A, Panico S, Mattiello A, Kaaks R, Teucher B, Katzke V, Kloss M, Curry L, Calboli F, Riboli E, Vineis P, Middleton L. Neurodegener Dis. 2015;15(6):331-8.

Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism. Janelidze S, Hertze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, Hansson O. Ann Clin Transl Neurol. 2015 Nov 20;3(1):12-20.

Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Janelidze S, Hertze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, Hansson O. Ann Clin Transl Neurol. 2015 Nov 20;3(1):12-20.

Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-sectional Cohort Study Evaluating the Effect of Arterial Stiffness. Anna-Märta Gustavsson, Erik Stomrud, Kasim Abul-Kasim, Lennart Minthon, Peter M. Nilsson, Oskar Hansson, Katarina Nägga. Cerebrovascular Diseases EXTRA, 2015;5:41–51.

CSF biomarkers and clinical progression of Parkinson disease. Hall S, Surova Y, Öhrfelt A, Zetterberg H, Lindqvist D, and Hansson O. Neurology, 2015 Jan 6;84(1):57-63.

2014

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid beta-Amyloid 42. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O. JAMA Neurol. 2014 Oct;71(10):1282-9.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. JAMA Psychiatry. 2014;71(10):1183-91.

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls. Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, & Nielsen HM. Acta Neuropathologica 2014, 127(5):633-643.

Flt3 ligand does not differentiate between Parkinsonian disorders. Silajdžić E, Constantinescu R, Holmberg B, Björkqvist M, & Hansson O. Movement Disorders 2014, 29(10):1319-1322.

Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, Nägga K, Londos E, Varghese S, Majbour NK, Al-Hayani A, El-Agnaf OM. Alzheimer’s Research & Therapy. 2014;6(3):25.

Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. Nielsen HM, Hall S, Surova Y, Nägga K, Nilsson C, Londos E, Minthon L, Hansson O, Wennström M. Nielsen HM et al. Journal of Alzheimer’s Disease. 2014;40(2):343-50.

2013

Cerebrospinal fluid inflammatory markers in Parkinson’s disease–associations with depression, fatigue, and cognitive impairment. Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O. Brain, Behavior, and Immunity. 2013;33:183-9.

Assessment of global and regional diffusion changes along white matter tracts in parkinsonian disorders by MR tractography. Surova Y, Szczepankiewicz F, Lätt J, Nilsson M, Eriksson B, Leemans A, Hansson O, van Westen D, Nilsson C. PloS One. 2013;8(6):e66022.

Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Boström F, Hansson O, Nielsen HM. PloS one. 2013;8(1):e53250.

Abeta1-15/16 as a potential diagnostic marker in neurodegenerative diseases. Nutu M, Bourgeois P, Zetterberg H, Portelius E, Andreasson U, Parent S, Lipari F, Hall S, Constantinescu R, Hansson O, Blennow K. et al. Neuromolecular Medicine. 2013;15(1):169-79.